131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging

Chen,Lichun; Wang,Liangliang; Yan,Jianghua; Ma,Chao; Lu,Jing; Chen,Guoqiang; Chen,Shengyou; Su,Fu; Wang,Weixing; Su,Xinhui

doi:10.3892/ijo.2016.3808

131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging

Authors:
- Lichun Chen
- Liangliang Wang
- Jianghua Yan
- Chao Ma
- Jing Lu
- Guoqiang Chen
- Shengyou Chen
- Fu Su
- Weixing Wang
- Xinhui Su
View Affiliations

Affiliations: Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, Fujian 361004, P.R. China, Cancer Research Center of Medical School, Xiamen University, Xiamen, Fujian 361102, P.R. China
Published online on: December 16, 2016 https://doi.org/10.3892/ijo.2016.3808
Pages: 649-659

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a co-receptor for vascular endothelial growth factor‑3 (VEGF‑3), neuropilin receptor type‑2 (NRP‑2) plays a central role in lymphangiogenesis and angiogenesis. Recently, mounting data of evidence show that NRP‑2 is overexpressed in several human cancers, and its overexpression is often associated with poor prognosis. Therefore, it is necessary for us to develop an affinity reagent for noninvasive imaging of NRP‑2 expression because it may be possible to provide early cancer diagnosis, more accurate prognosis, and better treatment planning. Due to their high affinity, and specificity, monoclonal antibodies (mAbs) have been considered attractive candidates for targeted cancer therapy and diagnostics. We recently generated and validated a monoclonal antibody that specifically binds NRP‑2 b1b2 domain with no cross‑reactivity to NRP‑1 b1b2 domain, also known to be overexpressed in a variety of cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging NRP‑2- positive tumors. Anti‑NRP‑2 monoclonal antibodies were prepared by hybridomas and were labeled with iodine‑131 by chloramine‑T method. The in vitro physicochemical properties of 131I‑anti‑NRP‑2 mAb was determined. Binding affinity and specificity of 131I‑anti‑NRP‑2 mAb to NRP‑2 were assessed using human lung adenocarcinoma A549 cells. Biodistribution and SPECT studies were performed in mice bearing A549 tumor xenografts to evaluate the in vivo performance of 131I‑anti‑NRP‑2 mAb. The preparation of anti‑NRP‑2 mAb was completed successfully by hybridoma with high purity (>95%) and specific for NRP‑2 b1b2 domain, but not NRP‑1 b1b2 domain. The radiosynthesis of 131I‑anti‑NRP‑2 mAb was completed successfully within 60 min with high labelling efficiency (94.69±3.63%), and radiochemical purity (98.56±0.48%). The resulting probe, 131I‑anti‑NRP‑2 mAb displayed excellent stability in PBS solution during 24-72 h. 131I‑anti‑NRP‑2 mAb showed high binding affinity with A549 cells (96.6±1.44 nM). In vivo biodistribution and SPECT studies demonstrated targeting of A549 glioma xenografts was NRP‑2 specific. The tumor uptake was 5.86±0.27% ID/g at 6 h, and kept at high level of 4.64±0.82% ID/g at 72 h‑post‑injection. The tumor to contralateral muscle ratio (T/NT) was 2.08±0.33 at 6 h, and reached the highest level of 3.83±0.18 at 72 h after injection. SPECT imaging studies revealed that 131I‑anti‑NRP‑2 mAb could clearly identify A549 tumors with good contrast, especially at 48‑72 h after injection. In conclusion, this study demonstrates that 131I‑anti‑NRP‑2 mAb exhibited highly selective uptake in NRP‑2‑expressing tumors, and may provide a promising SPECT probe for imaging NRP‑2 positive tumors.

View Figures

View References

1	Takagi S, Tsuji T, Amagai T, Takamatsu T and Fujisawa H: Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol. 122:90–100. 1987. View Article : Google Scholar : PubMed/NCBI
2	Raimondi C and Ruhrberg C: Neuropilin signalling in vessels, neurons and tumours. Semin Cell Dev Biol. 24:172–178. 2013. View Article : Google Scholar : PubMed/NCBI
3	Prud'homme GJ and Glinka Y: Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 3:921–939. 2012. View Article : Google Scholar : PubMed/NCBI
4	Geretti E, Shimizu A and Klagsbrun M: Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 11:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
5	Geretti E and Klagsbrun M: Neuropilins: Novel targets for antiangiogenesis therapies. Cell Adhes Migr. 1:56–61. 2007. View Article : Google Scholar
6	Chaudhary B, Khaled YS, Ammori BJ and Elkord E: Neuropilin 1: Function and therapeutic potential in cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
7	Plein A, Fantin A and Ruhrberg C: Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. Microcirculation. 21:315–323. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sulpice E, Plouët J, Bergé M, Allanic D, Tobelem G and Merkulova-Rainon T: Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood. 111:2036–2045. 2008. View Article : Google Scholar
9	Parker MW, Xu P, Li X and Vander Kooi CW: Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding toneuropilin-1. J Biol Chem. 287:11082–11089. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L and Alitalo K: Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 20:1462–1472. 2006. View Article : Google Scholar : PubMed/NCBI
11	Yuan L, Moyon D, Pardanaud L, Bréant C, Karkkainen MJ, Alitalo K and Eichmann A: Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development. 129:4797–4806. 2002.PubMed/NCBI
12	Zhang Y, Liu P, Jiang Y, Dou X, Yan J, Ma C, Fan Q, Wang W, Su F, Tang H, et al: High expression of neuropilin-1 associates with unfavorable clinicopathological features in hepatocellular carcinoma. Pathol Oncol Res. 22:367–375. 2016. View Article : Google Scholar
13	Hey-Cunningham AJ, Markham R, Fraser IS and Berbic M: Dysregulation of vascular endothelial growth factors and their neuropilin receptors in the eutopic endometrium of women with endometriosis. Reprod Sci. 20:1382–1389. 2013. View Article : Google Scholar : PubMed/NCBI
14	Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, et al: Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 6:e232082011. View Article : Google Scholar
15	Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, et al: Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Res. 73:7111–7121. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cao Y, Hoeppner LH, Bach S, E G, Guo Y, Wang E, Wu J, Cowley MJ, Chang DK, Waddell N, et al: Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin. Cancer Res. 73:4579–4590. 2013. View Article : Google Scholar : PubMed/NCBI
17	Dallas NA, Gray MJ, Xia L, Fan F, van Buren G II, Gaur P, Samuel S, Lim SJ, Arumugam T, Ramachandran V, et al: Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res. 14:8052–8060. 2008. View Article : Google Scholar : PubMed/NCBI
18	Dutta S, Roy S, Polavaram NS, Baretton GB, Muders MH, Batra S and Datta K: NRP2 transcriptionally regulates its downstream effector WDFY1. Sci Rep. 6:235882016. View Article : Google Scholar : PubMed/NCBI
19	Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, et al: Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 100:109–120. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dutta S, Roy S, Polavaram NS, Stanton MJ, Zhang H, Bhola T, Hönscheid P, Donohue TM Jr, Band H, Batra SK, et al: Neuropilin-2 regulates endosome maturation and EGFR trafficking to support cancer cell pathobiology. Cancer Res. 76:418–428. 2016. View Article : Google Scholar :
21	Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, et al: Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. Int J Cancer. 136:443–451. 2015. View Article : Google Scholar
22	Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 13:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, Jiang D, Barnhart TE, Yang Y and Cai W: ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur J Nucl Med Mol Imaging. 43:2169–2179. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yang Y, Chen N, Li Z, Wang XJ, Wang SY, Tingwu, Luo FH and Yan JH: Preparation, purification, and identification of a monoclonal antibody against NRP2 b1b2 domain. Monoclon Antib Immunodiagn Immunother. 34:354–359. 2015. View Article : Google Scholar : PubMed/NCBI
25	Su X, Chen Q, Chen W, Chen T, Li W, Li Y, Dou X, Zhang Y, Shen Y, Wu H, et al: Mycoepoxydiene inhibits activation of BV2 microglia stimulated by lipopolysaccharide through suppressing NF-κB, ERK 1/2 and toll-like receptor pathways. Int Immunopharmacol. 19:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
26	Dou X, Yan J, Zhang Y, Liu P, Jiang Y, Lv S, Zeng F, Chen X, Wang S, Zhang H, et al: SPECT imaging of neuropilin receptor type-1 expression with ¹³¹I-labeled monoclonal antibody. Int J Oncol. 49:961–970. 2016.PubMed/NCBI
27	Guo Z, Gao M, Zhang D, Li Y, Song M, Zhuang R, Su X, Chen G, Liu T, Liu P, et al: Simultaneous SPECT imaging of multi-targets to assist in identifying hepatic lesions. Sci Rep. 6:288122016. View Article : Google Scholar : PubMed/NCBI
28	Su X, Cheng K, Liu Y, Hu X, Meng S and Cheng Z: PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule. Amino Acids. 47:1409–1419. 2015. View Article : Google Scholar : PubMed/NCBI
29	Su X, Cheng K, Jeon J, Shen B, Venturin GT, Hu X, Rao J, Chin FT, Wu H and Cheng Z: Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors. Mol Pharm. 11:3947–3956. 2014. View Article : Google Scholar : PubMed/NCBI
30	Guo Z, Gao M, Song M, Shi C, Zhang P, Xu D, You L, Zhuang R, Su X, Liu T, et al: Synthesis and evaluation of (99m)Tc-labeled dimeric folic acid for FR-targeting. Molecules. 21:E8172016. View Article : Google Scholar : PubMed/NCBI
31	Chen H, Chédotal A, He Z, Goodman CS and Tessier-Lavigne M: Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 19:547–559. 1997. View Article : Google Scholar : PubMed/NCBI
32	Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, Muders MH and Datta K: Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res. 73:160–171. 2013. View Article : Google Scholar :
33	Parker MW and Vander Kooi CW: Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. Anal Biochem. 453:4–6. 2014. View Article : Google Scholar : PubMed/NCBI
34	Jubb AM, Sa SM, Ratti N, Strickland LA, Schmidt M, Callahan CA and Koeppen H: Neuropilin-2 expression in cancer. Histopathology. 61:340–349. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD: Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
36	Khan AH and Sadroddiny E: Licensed monoclonal antibodies and associated challenges. Hum Antibodies. 23:63–72. 2015. View Article : Google Scholar
37	Aung NY, Ohe R, Meng H, Kabasawa T, Yang S, Kato T and Yamakawa M: Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages. PLoS One. 11:e01473582016. View Article : Google Scholar : PubMed/NCBI